Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.

Karima Saboundji,Jean-Bernard Auliac,Maurice Pérol,Géraldine François,Henri Janicot,Marie Marcq,Catherine Dubos-Arvis,Aldo Renault,Florian Guisier,Luc Odier,Radj Gervais,Christos Chouaïd

Targeted oncology（2018）

引用 39|浏览49

暂无评分

摘要

In this non-selected population, osimertinib had remarkable efficacy in NSCLC patients with LM irrespective of the presence of the EGFR-T790M-resistance mutation. Osimertinib efficacy was rapid in several patients, even some with poor performance status.

查看译文

关键词

leptomeningeal metastases,osimertinib,lung cancer,egfr-mutated,non-small,egfr-tyrosine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要